Boryeong lands record $277m Taxotere supply deal with Chinese pharma firm

Boryeong has secured the largest overseas supply contract in its history, leveraging the original anticancer drug Taxotere (docetaxel) — the first major result since the company acquired global rights to the product from Sanofi in May.

Boryeong announced Tuesday that it had signed a contract with Chinese pharmaceutical company Yifan Pharmaceutical to supply Taxotere to the Chinese market.

The deal runs for seven years and is valued at $277.14 million, making it the largest single supply contract Boryeong has ever signed.

The contract includes annual minimum purchase obligations and compensation clauses that apply if actual purchase volumes fall short of agreed quantities, securing both long-term revenue visibility and sales stability. Revenue from the contract will be recognized incrementally in line with the supply schedule.

The deal is significant because it locks in seven years of demand in China — the largest market by sales among the countries covered by the Taxotere acquisition. Since acquiring Taxotere, Boryeong has moved beyond simple sales to directly managing the product's full lifecycle, including country-by-country partnerships, quality control and supply chain operations.

The synergy with local partner Yifan Pharmaceutical is also drawing attention. Listed on the Shenzhen Stock Exchange, Yifan drove strong growth by handling sales and marketing in China for Xeloda — Roche's original cytotoxic anticancer drug acquired by Germany's Cheplapharm — and is regarded as having unrivaled expertise in local oncology drug approvals and distribution network management.

Boryeong plans to maintain stable supply to China through its existing production system while gradually shifting Taxotere manufacturing to its Yesan Campus in South Chungcheong Province, following technology transfers and country-specific regulatory approvals. The Yesan Campus is a key facility equipped with high-potency active pharmaceutical ingredient containment systems, aseptic processes and finished-product manufacturing capabilities for cytotoxic anticancer drugs.

The company intends to apply to Taxotere the same know-how it used to bring Gemzar and Alimta — both acquired from Eli Lilly — into in-house production. Once internalization is complete, Boryeong expects to cut outsourcing costs, improve its cost structure and maximize profitability. The company also plans to internalize active pharmaceutical ingredient production and pursue formulation improvements, consolidating brand, regulatory, quality, production and supply functions under one roof while expanding into global contract development and manufacturing.

Kim Seong-jin, Boryeong's executive vice president and chief strategy officer, said the company had "proven that the global essential medicines business is translating into real earnings by securing seven years of long-term demand in China, Taxotere's largest market." He added that Boryeong would "refine the business model encompassing original brand acquisition, quality control, production internalization and global supply to achieve overseas sales of more than 300 billion won ($217 million) by 2030."

Analysts say Boryeong's distinctive LBA (Legacy Brands Acquisition) strategy — acquiring proven original assets from multinational pharmaceutical companies, internalizing production at its own factories and expanding global distribution — has moved beyond mere rights acquisition and entered a phase of generating stable cash flow.